Altai Library Blog November 18, 2020

New Protocol: Pembrolizumab + chemotherapy for previously untreated advanced triple-negative breast cancer

New Protocol: Pembrolizumab + chemotherapy for previously untreated advanced triple-negative breast cancer
Placebo controlled phase 3 trial Previously untreated locally recurrent inoperable or metastatic triple negative breast cancer Pembrolizumab + chemo (n=566) vs. Placebo + chemo (n=281) Chemo: Weekly PACLitaxel or weekly nab-PACLitaxel or CARBOplatin/gemcitabine Median PFS: 7.5 vs. 5.6 mos in ITT population (NS) 9.7 vs. 5.6 mos in CPS >= 10 (HR:0.65 [0.49-0.86]) Grade 3-4 immune-mediated AEs: 5.5% vs. 0%
Journal of Clinical Oncology 2020;38(15_suppl):1000 Cortes J, et al. KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. https://doi.org/10.1200/JCO.2020.38.15_suppl.1000
Reviewed by Ulas Darda Bayraktar, MD on Nov 18, 2020

Altai Chemo Planner